Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Editas Medicine, Inc.    EDIT

EDITAS MEDICINE, INC.

(EDIT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/24/2020 11/25/2020 11/27/2020 11/30/2020 12/01/2020 Date
29.02(c) 29.45(c) 31.34(c) 30.59(c) 31.9 Last
716 574 503 712 700 933 1 139 456 1 830 663 Volume
-1.06% +1.48% +6.42% -2.39% +4.28% Change
More quotes
Financials (USD)
Sales 2020 85,2 M - -
Net income 2020 -101 M - -
Net cash position 2020 448 M - -
P/E ratio 2020 -15,9x
Yield 2020 -
Sales 2021 27,7 M - -
Net income 2021 -217 M - -
Net cash position 2021 391 M - -
P/E ratio 2021 -8,86x
Yield 2021 -
Capitalization 1 891 M 1 891 M -
EV / Sales 2020 16,9x
EV / Sales 2021 54,1x
Nbr of Employees 208
Free-Float 98,4%
More Financials
Company
Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid... 
More about the company
Notations Surperformance© of Editas Medicine, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about EDITAS MEDICINE, INC.
11/10EDITAS MEDICINE : Reports Inducement Grants to New Chief Medical Officer
AQ
11/10Editas Medicine Reports Inducement Grants to New Chief Medical Officer
GL
11/09EDITAS MEDICINE : to Present at Barclays Gene Editing & Gene Therapy Summit
AQ
11/09Editas Medicine to Present at Barclays Gene Editing & Gene Therapy Summit
GL
11/09EDITAS MEDICINE : Appoints Lisa A. Michaels, M.D., as Chief Medical Officer
AQ
11/09Editas Medicine Appoints Lisa A. Michaels, M.D., as Chief Medical Officer
GL
11/06EDITAS MEDICINE : Management's Discussion and Analysis of Financial Condition an..
AQ
11/05EDITAS : 3Q Earnings Snapshot
AQ
11/05EDITAS MEDICINE, INC. : Results of Operations and Financial Condition, Financial..
AQ
11/05EDITAS MEDICINE : November 2020 Corporate Presentation
PU
11/05EDITAS MEDICINE : Announces Third Quarter 2020 Results and Update
AQ
11/05Editas Medicine Announces Third Quarter 2020 Results and Update
GL
10/29EDITAS MEDICINE : to Host Conference Call Discussing Third Quarter 2020 Results ..
AQ
10/29Editas Medicine to Host Conference Call Discussing Third Quarter 2020 Results..
GL
10/01EDITAS MEDICINE : October 2020 Corporate Presentation
PU
More news
News in other languages on EDITAS MEDICINE, INC.
07/07Stellenstreichungen bei britischen Tageszeitungen
07/07Reach, éditeur du Daily Mirror et du Daily Express, supprime 550 emplois
2018WALL STREET STOCK EXCHANGE : Wall Street finit dans le désordre, le pétrole pèse
More news
Chart EDITAS MEDICINE, INC.
Duration : Period :
Editas Medicine, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EDITAS MEDICINE, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 38,00 $
Last Close Price 30,59 $
Spread / Highest target 96,1%
Spread / Average Target 24,2%
Spread / Lowest Target -54,2%
EPS Revisions
Managers
NameTitle
Cynthia L. Collins President, Chief Executive Officer & Director
James C. Mullen Chairman
Harry R. Gill Senior Vice President-Operations
Michelle Robertson Treasurer, Chief Financial & Accounting Officer
Charles Albright Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
EDITAS MEDICINE, INC.3.31%1 891
MODERNA, INC.680.88%60 441
LONZA GROUP AG61.27%46 692
CELLTRION, INC.87.85%41 055
IQVIA HOLDINGS INC.9.37%32 400
SEAGEN INC.49.05%30 708